Early Retinal and Choroidal Coat Thickness Changes after Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema
Early Retinal and Choroidal Coat Thickness Changes after Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema
Background: Intravitreal steroid injection is one of the treatmentoptions for diabetic macular edema. Dexamethasone implant isthe most novel form of intravitreal steroid therapy. Improvementin macular thickness is a well-known effect of Dexamethasoneimplant however, subfoveal choroidal coat thickness changes requireinvestigation.Aims: To evaluate the early central macular thickness and subfovealchoroidal thickness alterations after single-dose dexamethasoneimplant injection in diabetic macular edema.Study Design: Cross-sectional study.Methods: We identified 29 patients with diabetic macular edema(29 eyes) who underwent optical coherence tomography andfundus fluorescein angiography. All patients received a single-doseintravitreal Dexamethasone implant and were followed up for centralmacular thickness and subfoveal choroidal thickness alterations for 1hour, 1 week, 1 month, and 3 months post-injection.Results: The preoperative mean central macular thickness andsubfoveal choroidal thickness measurements were 592.3±122.3(412–879) μm and 264.8±53.7 (165–397) μm, respectively. Centralmacular thickness measurements decreased significantly in the firsthour (p
___
- Boyer DS, Faber D, Gupta S, Tabandeh H, Li XY, Liu CC, et al. Dexamethasone
intravitreal implant for treatment of diabetic macular edema in vitrectomized patients.
Retina 2011;31:915-23.
- Gillies MC, Lim LL, Campain A, Quin GJ, Salem W, Li J, et al. A randomized clinical
trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic
macular edema: the BEVORDEX study. Ophthalmology 2014;121:2473-81.
- Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, et al.
Dexamethasone intravitreal implant in combination with laser photocoagulation for
the treatment of diffuse diabetic macular edema. Ophthalmology 2013;120:1843-51.
- Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou
C, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery
system in patients with diabetic macular edema. Arch Ophthalmol 2010;128:289-96.
- Sonoda S, Sakamoto T, Yamashita T, Otsuka H, Shirasawa M, Kakiuchi N, et al.
Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness
in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 2014;55:3979-85.
- Okamoto M, Matsuura T, Ogata N. Effects of panretinal photocoagulation on
choroidal thickness and choroidal blood flow in patients with severe nonproliferative
diabetic retinopathy. Retina 2016;36:805-11.
- Ozdogan Erkul S, Kapran Z, Uyar OM. Quantitative analysis of subfoveal choroidal
thickness using enhanced depth imaging optical coherence tomography in normal
eyes. Int Ophthalmol 2014;34:35-40.
- Kim JT, Lee DH, Joe SG, Kim JG, Yoon YH. Changes in choroidal thickness in
relation to the severity of retinopathy and macular edema in type 2 diabetic patients.
Invest Ophthalmol Vis Sci 2013;54:3378-84.
- Regatieri CV, Branchini L, Carmody J, Fujimoto JG, Duker JS. Choroidal thickness
in patients with diabetic retinopathy analyzed by spectral-domain optical coherence
tomography. Retina 2012;32:563-8.
- Rayess N, Rahimy E, Ying GS, Bagheri N, Ho AC, Regillo CD, et al. Baseline
choroidal thickness as a predictor for response to anti-vascular endothelial growth
factor therapy in diabetic macular edema. Am J Ophthalmol 2015;159:85-91.
- Chung YR, Kim JW, Kim SW, Lee K. Choroidal thickness in patients with
central serous chorioretinopathy: assessment of Haller and Sattler layers. Retina
2016;36:1652-7.
- Cheng H, Kaszubski PA, Hao H, Saade C, Cunningham C, Freund KB, et al. The
Relationship between Reticular Macular Disease and Choroidal Thickness. Curr Eye
Res 2016;41:1492-7.
- Spaide RF. Enhanced depth imaging optical coherence tomography of retinal
pigment epithelial detachment in age related macular degeneration. Am J Ophthalmol
2009;147:644-52.
- Nagaoka T, Kitaya N, Sugawara R, Yokota H, Mori F, Hikichi T, et al. Alteration
of choroidal circulation in the foveal region in patients with type 2 diabetes. Br J
Ophthalmol 2004;88:1060-3.
- Cao J, McLeod S, Merges CA, Lutty GA. Choriocapillaris degeneration and related
pathologic changes in human diabetic eyes. Arch Ophthalmol 1998;116:589-97.
- Melancia D, Vicente A, Cunha JP, Abegão Pinto L, Ferreira J. Diabetic choroidopathy:
a review of the current literature. Graefes Arch Clin Exp Ophthalmol 2016;254:1453-
61.
- Lutty GA. Effects of diabetes on the eye. Invest Ophthalmol Vis Sci 2013;54:81-7.
- McLeod DS, Lutty GA. High-resolution histologic analysis of the human choroidal
vasculature. Invest Ophthalmol Vis Sci 1994;35:3799-811.
- Kim M, Cho YJ, Lee CH, Lee SC. Effect of intravitreal dexamethasone implant on
retinal and choroidal thickness in refractory diabetic macular oedema after multiple
anti-VEGF injections. Eye (Lond) 2016;30:718-25.
- Roohipoor R, Sharifian E, Ghassemi F, Riazi-Esfahani M, Karkhaneh R, Fard Ma,
et al. Choroidal thickness changes in proliferatıve diabetic retinopathy treated with
panretinal photocoagulation versus panretinal photocoagulation with intravitreal
bevacizumab. Retina 2016;36:1997-2005.
- Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, et al. Long-term effect
of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular
edema. Retina 2008;28:1053-60.
- Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al.
Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least
3 years in patients with diabetic macular edema. Ophthalmology 2012;119:2125-32.
- Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, et al. Threeyear,
randomized, sham-controlled trial of dexamethasone intravitreal implant in
patients with diabetic macular edema. Ophthalmology 2014;121:1904-14.
- Bressler SB, Qin H, Beck RW, Chalam KV, Kim JE, Melia M, Wells JA 3rd; Diabetic
Retinopathy Clinical Research Network. Factors associated with changes in visual
acuity and central subfield thickness at 1 year after treatment for diabetic macular
edema with ranibizumab. Arch Ophthalmol 2012;130:1153-61.
- Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars plana
vitrectomy with internal limiting membrane removal in diabetic macular edema.
Retina 2007;27:557-66.
- Callanan DG, Gupta S, Boyer DS, Ciulla TA, Singer MA, Kuppermann BD, et al.
Dexamethasone intravitreal implant in combination with laser photocoagulation for
the treatment of diffuse diabetic macular edema. Ophthalmology 2013;120:1843-51.
- Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple
intravitreal injections of ranibizumab in patients with center-involving clinically
significant diabetic macular edema. Ophthalmology 2006;113:1706-12.
- No authors listed. Photocoagulation for diabetic macular edema. Early Treatment
Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy
Study research group. Arch Ophthalmol 1985;103:1796-806.
- Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic
population. Ophthalmology 1998;105:998-1003.